Visualitza per autor "Heinrich, Michael C."
Ara mostrant els elements 1-4 d 4
-
A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor
Pantaleo, Maria Abbondanza; Heinrich, Michael C.; Italiano, Antoine; Valverde Morales, Claudia Maria; Schöfski, Patrick; Grignani, Giovanni (BMC, 2022-05-06) -
Avapritinib in unresectable or metastatic PDGFRA D842V - mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
Jones, Robin L.; Serrano Garcia, César; von Mehren, Margaret; Heinrich, Michael C.; Kang, Yoon-Koo; George, Suzanne (Elsevier, 2021-03) -
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
Bauer, Sebastian; Heinrich, Michael C.; Serrano Garcia, César; Gelderblom, Hans; George, Suzanne; Zalcberg, John (American Association for Cancer Research, 2021-12-01) -
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial
Schöfski, Patrick; Heinrich, Michael C.; Bauer, Sebastian; Serrano Garcia, César; Gelderblom, Hans; George, Suzanne; Zalcberg, John (BMC, 2022-12-13)